<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01252914</url>
  </required_header>
  <id_info>
    <org_study_id>GCF-019</org_study_id>
    <nct_id>NCT01252914</nct_id>
  </id_info>
  <brief_title>A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent</brief_title>
  <official_title>A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of one iStent supra stent in
      the reduction of intraocular pressure associated with primary open-angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study assesses the efficacy and safety of one iStent supra stent in the reduction of
      intraocular pressure associated with primary open-angle glaucoma.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2010</start_date>
  <completion_date type="Anticipated">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean diurnal Intraocular Pressure reduction of greater than or equal to 20% at month 12 vs. baseline</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean diurnal Intraocular Pressure &lt; 18 mmHg at month 12</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>0-61 months</time_frame>
    <description>Rate of ocular adverse events through 61 months
Findings from Intraocular Pressure, best corrected visual acuity, visual field, specular microscopy measurements
Findings from slit-lamp, fundus and gonioscopic examinations</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Subject With Primary Open-angle Glaucoma (POAG)</condition>
  <arm_group>
    <arm_group_label>One iStent Supra Stent and medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent Supra Stent</intervention_name>
    <description>Implantation of one iStent Supra Stent through a small temporal clear corneal incision</description>
    <arm_group_label>One iStent Supra Stent and medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with primary open-angle glaucoma (POAG)

          -  Subjects on two topical hypotensive medications

        Exclusion Criteria:

          -  Traumatic, uveitic, neovascular, or angle closure glaucoma

          -  Fellow eye already enrolled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilit Voskanyan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SV Malayan Ophthalmological Center, Yerevan, Armenia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>S.V. Malayan Ophthalmology Centre</name>
      <address>
        <city>Yerevan</city>
        <zip>375108</zip>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Armenia</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open angle</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Surgery</keyword>
  <keyword>Ocular Hypertension</keyword>
  <keyword>Eye Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

